Compare · IOVA vs NXTC
IOVA vs NXTC
Side-by-side comparison of Iovance Biotherapeutics Inc. (IOVA) and NextCure Inc. (NXTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IOVA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while NXTC focuses on Biotechnology: Pharmaceutical Preparations.
- IOVA is the larger of the two at $3.59B, about 122.5x NXTC ($29.3M).
- IOVA has been more active in the news (16 items in the past 4 weeks vs 12 for NXTC).
- IOVA has more recent analyst coverage (21 ratings vs 4 for NXTC).
- Company
- Iovance Biotherapeutics Inc.
- NextCure Inc.
- Price
- -
- -
- Market cap
- $3.59B
- $29.3M
- 1M return
- -47.40%
- -
- 1Y return
- +211.24%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 16
- 12
- Recent ratings
- 21
- 4
Iovance Biotherapeutics Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
NextCure Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Latest IOVA
- Interim CEO & General Counsel Vogt Frederick G exercised 200,000 shares at a strike of $7.55 and covered exercise/tax liability with 191,303 shares, increasing direct ownership by 1% to 604,144 units (SEC Form 4) to cover withholding tax
- Chief Commercial Officer Kirby Daniel Gordon converted options into 10,000 shares and covered exercise/tax liability with 3,935 shares, increasing direct ownership by 4% to 160,576 units (SEC Form 4) (withholding obligation)
- Iovance Biotherapeutics to Present at Upcoming Conference
- Chief Financial Officer Roche Corleen M. converted options into 12,500 shares and covered exercise/tax liability with 5,311 shares, increasing direct ownership by 25% to 35,946 units (SEC Form 4) (withholding obligation)
- SEC Form SCHEDULE 13G filed by Iovance Biotherapeutics Inc.
- Iovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by Iovance Biotherapeutics Inc.
- Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
- SEC Form 8-K filed by Iovance Biotherapeutics Inc.
Latest NXTC
- Amendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.
- Large owner Adar1 Capital Management, Llc bought $62,897 worth of shares (12,333 units at $5.10) (SEC Form 4)
- SEC Form 10-Q filed by NextCure Inc.
- NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
- Large owner Adar1 Capital Management, Llc bought $23,899 worth of shares (4,686 units at $5.10) (SEC Form 4)
- SEC Form EFFECT filed by NextCure Inc.
- SEC Form 424B3 filed by NextCure Inc.
- Amendment: SEC Form S-4/A filed by NextCure Inc.
- Amendment: SEC Form S-4/A filed by NextCure Inc.